Dana Mead joined Kleiner Perkins Caufield & Byers as a partner in May 2005 to work in the life sciences practice.

For the past 28 years, Dana's career has focused on identifying new medical technologies, developing new markets and therapies, and building world-class management teams. He has worked with physician thought leaders around the world representing 10 different medical specialties. At KPCB, Dana leverages experience gained from his venture-funded, start-up management roles and board participation to support entrepreneurs and innovators dedicated to making a real difference in the lives of millions suffering from life-limiting disease.

Prior to joining KPCB, Dana was President of Guidant Vascular Intervention, a fully integrated billion dollar division with over 4500 employees. Since joining Guidant in 1992, he held positions of increasing responsibility including Vice President and General Manager, Cardiac & Vascular Surgery; Vice President and General Manager, Stents, Vascular Intervention Group; President, Japan and A/P Operations based in Tokyo; and Vice President, Corporate Relations and Policy with responsibility for investor relations, corporate communications, corporate marketing and public policy initiatives. Prior to joining Guidant, Dana worked in various sales and marketing roles at Allergan, Inc. and Johnson & Johnson. Dana serves on the boards of Apnicure, Corventis, Inspire Medical Systems, intersect ENT, Invuity, Navigenics, Pulmonx, Spiracur, Spinal Modulation and Voyage Medical. He was formerly a director of the Cardiovascular Research Foundation (CRF), Aesthera (acquired by Solta [SLTM]) and OtisMed (acquired by Stryker [SYK]).

Dana also serves on the boards of the California Healthcare Institute (CHI), Lucile Packard Children's Hospital at Stanford and is Chair of the Lafayette College West Coast Advisory Council.

A native of Connecticut, Dana received his BA from Lafayette College and holds an MBA from the University of Southern California.